Bassel Sabri: So, Egypt’s private hospital market is consolidating, and specialist care is now in play. Alameda, backed by $190 million in private equity, is reportedly negotiating control of a major eye hospital chain. Britain’s Moorfields has also held talks in the new capital. So, who will own Egypt’s next generation of specialist hospitals?
Well, joining me now is Dr. Ihab Othman, founder and chairman of Eye World Hospital. Thank you for joining us once more, Ihab.
Dr. Ihab Othman: Always a pleasure, Bassel. Thank you.
Bassel Sabri: So, you have run Eye World as an independent hospital for almost two decades, if my information is correct. Now, as bigger groups move into specialist care, what does it take to grow without giving up control?
Dr. Ihab Othman: You know, if you have building one and you want to sell, you will sell low. If you have building one plus building two, and you’re building a practice and capacity, then we can negotiate whatever you want. So this is the thing, you know, being [unclear: “a moot”] in business. Meaning that if anybody wants to have a [unclear: “next door SIM building sim facility”], he will not be a competitor, because we’re still building up quality and brand depending on personnel.
And this is in contrast to high-volume, high-building capacities that would depend on insurance or third party or the brand of the [unclear: “need”]. Egypt still wants to have an individual that would be trusted, especially in the eye business, that you would give him your eyes to have a better sight or better looks, or a better feeling of comfort about [unclear: “once. Once a sense in life as well”]. So this is a big difference between, you know, the big players and the solo players on the market, as well as [unclear: “that would send”] all the changes that are happening in the Egyptian market right now.
Bassel Sabri: Now, talking about the big players, you’ve heard me talk about Alameda. Alameda is reportedly negotiating its way into iCare. Why is iCare attracting consolidators at the moment, in your opinion?
Dr. Ihab Othman: Because iCare depends on high volume, low bed intensity. You know, whenever you buy oncology centers or rehabilitation centers or major surgery centers, you count the beds. You say, this is a 400-bed facility, this is a 200-bed facility, and you start to put a price on the bed, [unclear: “meaning the bed with the floor coming in for us”]. For the eye business, when it is specialized, it depends on high volume, low bed intensity, because we can recycle most of our surgeries. Whenever possible, they are under local anesthesia, and the hospital stay should not be more than two hours, you know, the patient as an inpatient on the surgery. So the reshuffling of the beds is a very important saving of capacity for the business when you think about it.
Also, our business counts on cash and an elective mix of procedures that will bring in cash, you know, so you don’t have to wait for third-party payers that would negotiate the payment terms and then start to discuss per patient, and all the headache that comes with insurance and third-party payers. Also, our technology is repeatable, meaning that if you do a cataract surgery using the phacoemulsification machine, it’s reproducible, you know, that would depend on high patient volume, and then the results are very consistent.
Add to this, with the building up of the capacity, [unclear: “versions that that would do”] high-volume surgery comes the premium and elective high-price services: the premium intraocular lenses that would allow you to see from far and near without needing glasses, the toric lenses, the special conditions that would need state-of-the-art quality that we can provide, and also the regional export ability, because, you know, Egypt is within four hours’ flight from 500 million people. You know, the radius of citizens around us, if within 3,000 km, is 500 million people. Imagine that one of our targets is to get a million people per year for the next three years to have in-house management and treatment, especially in the premium quality services that we definitely can provide, among an aging population.
Bassel Sabri: [unclear: “Having so many, so many to be done for the writes”] Doctor, have I, you know, just looking at the deal, we were talking about the Alameda deal. The fund selling that stake has held it since 2012. Why is it so hard for investors to exit Egyptian healthcare, in your opinion, when so many issues?
Dr. Ihab Othman: You know, it’s all related to economics and politics. In economics, you know, the currency kind of destroys the U.S. dollar returns. So the funds that were invested in 2012 survived through the 2016 float. Whenever you remember, we had the November float, when the currency really bumped, the Egyptian pound versus the dollar lost a significant amount of its capacity. And then we had the 2022 to 2024 devaluation, plus the foreign exchange shortages. So these are the main impacts on the revenues.
Also, by nature, the business in health has few natural buyers. So when Alameda steps in with this huge investment and starts to expand, the turnover is kind of slow. Also, there is what we call the founder-doctor holdup. Because if you have 51% on paper, when it comes to the health sector, it doesn’t mean that you own 51%, because there are always patients that come for the name of the doctor, by word of mouth, by the experience, by the doctor’s referral itself. So whenever you come and you count only the buildings and the instrumentation, you value the name by putting an add-on on the prices, and you do not involve doctors as partners, at least in the short-term strategy, three to five years, or better, five to ten years’ strategy. So you lose 30% of your business immediately.
Bassel Sabri: The doctors are more important than the brand.
Dr. Ihab Othman: Definitely, yes. When you go to specialty or you go to subspecialty, because, you know, the way the businesses are in our countries, patients who trust us, especially in sensitive issues like the eye, when you deal with the vision of a child or the vision of a grown-up, or a complication of diabetes that is affecting the eye, the word of mouth built up the brand that is still named after the doctor.
People would come from the level of trust and would ask you where they should go to have dental care, or to have dermatology care, or cancer care, or whatever, because we built up over the years this very strong relationship, right? [unclear: “I if I would, I would. No, I don’t need. Just for a second.”] You know, if I would call a colleague that is famous in his line of work in ophthalmology, “Mohammed, come. I need you to present something on the presentation for the doctors in my hospital,” he would definitely come. But if a brand calls him in, there will be so many justifications for, “Yeah, I might consider. Maybe yes, maybe not.” Or so.
Bassel Sabri: Well, yeah, I get your point. Absolutely. And, you know, I wish we had more time for this discussion, but thank you for this valuable, insanely valuable insight into the transformation that’s happening in specialized healthcare at the moment. Doctor Ihab, as usual, it’s been a pleasure. Thank you very much for joining in.
Dr. Ihab Othman: Thank you.